Defining Successful Treatment Outcome in Depression Using the PHQ-9: a Comparison of Methods
Overview
Authors
Affiliations
Background: Although the PHQ-9 is widely used in primary care, little is known about its performance in quantifying improvement. The original validation study of the PHQ-9 defined clinically significant change as a post-treatment score of ≤9 combined with improvement of 50%, but it is unclear how this relates to other theoretically informed methods of defining successful outcome. We compared a range of definitions of clinically significant change (original definition, asymptomatic criterion, reliable and clinically significant change criteria a, b and c) in a clinical trial of a community-level depression intervention.
Method: Randomised Control Trial of collaborative care for depression. Levels of agreement were calculated between the standard definition, other definitions, and gold-standard diagnostic interview.
Results: The standard definition showed good agreement (kappa>0.60) with the other definitions and had moderate, though acceptable, agreement with the diagnostic interview (kappa=0.58). The standard definition corresponded closely to reliable and clinically significant change criterion c, the recommended method of quantifying improvement when clinical and non-clinical distributions overlap.
Limitations: The absence of follow-up data meant that an asymptomatic criterion rather than remission or recovery criteria were used.
Conclusion: The close agreement between the standard definition and reliable and clinically significant change criterion c provides some support for the standard definition of improvement. However, it may be preferable to use a reliable change index rather than 50% improvement. Remission status, based on the asymptomatic range and a lower PHQ-9 score, may provide a useful additional category of clinical change.
Medina S, Forero C, Sanabria-Mazo J, Rodriguez-Freire C, Navarrete J, ODaly O Brain Behav. 2025; 15(3):e70380.
PMID: 40022281 PMC: 11870833. DOI: 10.1002/brb3.70380.
Bah A, Wurie H, Samai M, Horn R, Ager A J Affect Disord Rep. 2025; 19():100852.
PMID: 39850399 PMC: 11752488. DOI: 10.1016/j.jadr.2024.100852.
Zainal N, Benjet C, Albor Y, Nunez-Delgado M, Zambrano-Cruz R, Contreras-Ibanez C Int J Methods Psychiatr Res. 2025; 34(1):e70005.
PMID: 39780444 PMC: 11711205. DOI: 10.1002/mpr.70005.
Moriarty A, Paton L, Snell K, Archer L, Riley R, Buckman J BMJ Ment Health. 2024; 27(1).
PMID: 39467616 PMC: 11529744. DOI: 10.1136/bmjment-2024-301226.
James K, Saxon D, Barkham M Adm Policy Ment Health. 2024; 51(6):970-987.
PMID: 39153042 PMC: 11489297. DOI: 10.1007/s10488-024-01403-0.